Table 1.
Profiles of all analyzed patients with WHO grade II‐IV gliomas (n = 130)
| AA, 19q‐intact | AA, 19q‐loss | AO | GBM, 19q‐intact | GBM, 19q‐loss | |
|---|---|---|---|---|---|
| n | 12 | 7 | 23 | 74 | 14 |
| Age, years | |||||
| Median (SD) | 43 (14) | 40 (11) | 49 (15) | 62 (15) | 63 (12) |
| Sex, male | |||||
| n (%) | 9 (75) | 6 (86) | 11 (48) | 50 (68) | 10 (71) |
| Tumor side | |||||
| Right | 7 | 4 | 13 | 36 | 8 |
| Left | 0 | 3 | 9 | 29 | 6 |
| Bilateral | 3 | 0 | 1 | 6 | 0 |
| Midline | 2 | 0 | 0 | 3 | 0 |
| Tumor location | |||||
| Frontal | 6 | 7 | 14 | 34 | 6 |
| Temporal | 1 | 0 | 2 | 15 | 3 |
| Parietal | 1 | 0 | 3 | 12 | 5 |
| Occipital | 1 | 0 | 0 | 2 | 0 |
| Thalamus | 1 | 0 | 0 | 5 | 0 |
| Brain stem | 1 | 0 | 0 | 3 | 0 |
| Othera | 1 | 0 | 4 | 3 | 0 |
| Extent of resection | |||||
| GTR | 7 | 5 | 15 | 41 | 12 |
| PR | 1 | 2 | 5 | 10 | 1 |
| Biopsy | 4 | 0 | 3 | 23 | 1 |
| Adjuvant therapy (first line) | |||||
| RT + TMZ | 9 | 6 | 5 | 49 | 12 |
| RT + PAV | 1 | 0 | 1 | 17 | 2 |
| PAV | 0 | 1 | 15 | 0 | 0 |
| RT only | 1 | 0 | 1 | 5 | 0 |
| Otherb | 1 | 0 | 1 | 3 | 0 |
| Genetic status | |||||
| IDH | Mutant | Mutant | Mutant | Wild type | Wild type |
| 1p | Intact | Intact | Loss | Intact | Intact |
| 19q | Intact | Loss | Loss | Loss | Intact |
AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; GBM, glioblastoma; GTR, gross total removal; PR, partial removal.
a
Includes pineal lesion, insula, and involvement of the several lobes.
b
Includes temozolomide (TMZ) alone, radiation therapy (RT) with procarbazine, ACNU, and vincristine (PAV), or best supportive care.